Patrick M Sluss

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint Methodologies for measurement of cardiac markers
    Patrick M Sluss
    Pathology Service, Clinical Pathology Core Laboratories Special Chemistry, Pathology, Massachusetts General Hospital, Harvard Medical School, GRB554, 55 Fruit Street, Boston, MA 02114, USA Electronic address
    Clin Lab Med 34:167-85, viii. 2014
  2. ncbi request reprint Mass spectrometric and physiological validation of a sensitive, automated, direct immunoassay for serum estradiol using the Architect
    Patrick M Sluss
    Reproductive Endocrine Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Chim Acta 388:99-105. 2008
  3. pmc Genetic variation in the progesterone receptor gene and ovarian cancer risk
    Kathryn L Terry
    Obstetrics and Gynecology Epidemiology Center, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Am J Epidemiol 161:442-51. 2005
  4. pmc A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development
    Shelley S Tworoger
    Channing Division of Network Medicine, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 73:4810-9. 2013
  5. ncbi request reprint High-resolution reference ranges for estradiol, luteinizing hormone, and follicle-stimulating hormone in men and women using the AxSYM assay system
    Anand S Dighe
    Clinical Chemistry Laboratory, Department of Pathology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    Clin Biochem 38:175-9. 2005
  6. ncbi request reprint Sex hormone levels and risk of cardiovascular events in postmenopausal women
    Kathryn M Rexrode
    Division of Preventive Medicine, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 900 Commonwealth Ave E, Boston, Mass 02215, USA
    Circulation 108:1688-93. 2003
  7. ncbi request reprint Differential distribution of follistatin isoforms: application of a new FS315-specific immunoassay
    Alan L Schneyer
    Reproductive Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Clin Endocrinol Metab 89:5067-75. 2004
  8. pmc Blood and urine markers for ovarian cancer: a comprehensive review
    Kathryn L Terry
    Ob Gyn Center Epidemiology Center, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women s Hospital, Boston, MA, USA
    Dis Markers 20:53-70. 2004
  9. ncbi request reprint Improved detection of serum estradiol after sample extraction procedure
    Anand S Dighe
    Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Chem 50:764-6. 2004
  10. ncbi request reprint Establishment of a central laboratory serum tumor marker service on a consolidated immunodiagnostic platform: development of practice standards, service improvements, and operational efficiency
    Patrick M Sluss
    Department of Pathology and Laboratory Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Leadersh Manag Rev 18:25-31. 2004

Collaborators

Detail Information

Publications15

  1. doi request reprint Methodologies for measurement of cardiac markers
    Patrick M Sluss
    Pathology Service, Clinical Pathology Core Laboratories Special Chemistry, Pathology, Massachusetts General Hospital, Harvard Medical School, GRB554, 55 Fruit Street, Boston, MA 02114, USA Electronic address
    Clin Lab Med 34:167-85, viii. 2014
    ..How these principles are applied in the design of immunometric assays and how they influence assay performance in quantifying cardiac biomarkers in biologic fluids (serum or plasma) is discussed. ..
  2. ncbi request reprint Mass spectrometric and physiological validation of a sensitive, automated, direct immunoassay for serum estradiol using the Architect
    Patrick M Sluss
    Reproductive Endocrine Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Chim Acta 388:99-105. 2008
    ..The challenge for all currently available direct methods for measuring E(2) is to provide accuracy and precision across a wide dynamic range...
  3. pmc Genetic variation in the progesterone receptor gene and ovarian cancer risk
    Kathryn L Terry
    Obstetrics and Gynecology Epidemiology Center, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Am J Epidemiol 161:442-51. 2005
    ..76, 95% confidence interval: 0.62, 0.92). Associations were similar after stratifying by ovarian cancer histologies and risk factors...
  4. pmc A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development
    Shelley S Tworoger
    Channing Division of Network Medicine, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 73:4810-9. 2013
    ..This corresponds with biologic data that prolactin is etiologically important in tumor promotion...
  5. ncbi request reprint High-resolution reference ranges for estradiol, luteinizing hormone, and follicle-stimulating hormone in men and women using the AxSYM assay system
    Anand S Dighe
    Clinical Chemistry Laboratory, Department of Pathology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    Clin Biochem 38:175-9. 2005
    ..High-resolution reference ranges are essential for reproductive hormones due to the significant day-to-day variation seen with these analytes...
  6. ncbi request reprint Sex hormone levels and risk of cardiovascular events in postmenopausal women
    Kathryn M Rexrode
    Division of Preventive Medicine, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 900 Commonwealth Ave E, Boston, Mass 02215, USA
    Circulation 108:1688-93. 2003
    ..Despite diffuse effects of sex hormones on the cardiovascular system, few prospective studies have examined the relationship of plasma androgens and estrogens with risk of cardiovascular disease (CVD) in postmenopausal women...
  7. ncbi request reprint Differential distribution of follistatin isoforms: application of a new FS315-specific immunoassay
    Alan L Schneyer
    Reproductive Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Clin Endocrinol Metab 89:5067-75. 2004
    ..They also confirm that the source of FST in human serum is not the ovarian follicle...
  8. pmc Blood and urine markers for ovarian cancer: a comprehensive review
    Kathryn L Terry
    Ob Gyn Center Epidemiology Center, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women s Hospital, Boston, MA, USA
    Dis Markers 20:53-70. 2004
  9. ncbi request reprint Improved detection of serum estradiol after sample extraction procedure
    Anand S Dighe
    Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Chem 50:764-6. 2004
  10. ncbi request reprint Establishment of a central laboratory serum tumor marker service on a consolidated immunodiagnostic platform: development of practice standards, service improvements, and operational efficiency
    Patrick M Sluss
    Department of Pathology and Laboratory Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Leadersh Manag Rev 18:25-31. 2004
    ..Over the past decade, serum tumor marker testing in patient management has become more defined, resulting in increasing test volume and wider availability of assays on automated immunodiagnostic platforms...
  11. pmc p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer
    Karen S Anderson
    Cancer Vaccine Center, Department of Medical Oncology, Dana Farber Cancer Institute, HIM416, 77 Avenue Louis Pasteur, Boston, MA 02115, USA
    Cancer Epidemiol Biomarkers Prev 19:859-68. 2010
    ..This study examined the value of serum p53 autoantibodies (p53-AAb) as detection and prognostic biomarkers in ovarian cancer...
  12. pmc CA125 immune complexes in ovarian cancer patients with low CA125 concentrations
    Daniel W Cramer
    Department of Obstetrics and Gynecology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Chem 56:1889-92. 2010
    ..Because CA125 and MUC1 are related members of the mucin family, we sought to determine whether CICs might also exist for CA125 and interfere with its clinical assay...
  13. ncbi request reprint Age-related analysis of inhibin A, inhibin B, and activin a relative to the intercycle monotropic follicle-stimulating hormone rise in normal ovulatory women
    Nancy A Klein
    Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington 98105, USA
    J Clin Endocrinol Metab 89:2977-81. 2004
    ..Thus, the monotropic rise in FSH does not appear to result from changes in inhibin A or activin A, supporting the concept that inhibin B plays a critical role in mediating the FSH rise in older women...
  14. ncbi request reprint Endocrine assessment of relative reproductive age in normal eumenorrheic younger and older women across multiple cycles
    Tarun Jain
    Division of Reproduction Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Washington Medical Center, Seattle, USA
    Am J Obstet Gynecol 189:1080-4. 2003
    ..The aim of this study was to better characterize the ranges and intercycle variability for day 3 follicle-stimulating hormone, estradiol, and inhibin B levels in normal eumenorrheic women...
  15. ncbi request reprint Reproductive ageing and ovarian function: is the early follicular phase FSH rise necessary to maintain adequate secretory function in older ovulatory women?
    Karl R Hansen
    Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
    Hum Reprod 20:89-95. 2005
    ..The goal of this investigation was to determine if ovarian secretory capacity is dependent on relative FSH levels and if basal measures of ovarian reserve reflect ovarian secretory capacity...